Combined ASBT Inhibitor and FGF15 Treatment Improves Therapeutic Efficacy in Experimental Nonalcoholic SteatohepatitisSummary

Background & Aims: Pharmacologic agents targeting bile acid signaling show promise for treating nonalcoholic steatohepatitis (NASH). However, clinical findings suggest that new treatment strategies with enhanced therapeutic efficacy and minimized undesired effects are needed. This preclinical st...

ver descrição completa

Detalhes bibliográficos

Principais autores:	David J. Matye, Huaiwen Wang, Wenyi Luo, Rachel R. Sharp, Cheng Chen, Lijie Gu, Kenneth L. Jones, Wen-Xing Ding, Jacob E. Friedman, Tiangang Li
Formato:	Artigo
Idioma:	Inglês
Publicado em:	Elsevier 2021-01-01
coleção:	Cellular and Molecular Gastroenterology and Hepatology
Assuntos:	Bile Acids Fatty Liver CYP7A1 NASH Liver Fibrosis
Acesso em linha:	http://www.sciencedirect.com/science/article/pii/S2352345X21000849
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!